Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C.

Journal of gastroenterology - 1 Apr 2017

Morio Reona, Imamura Michio, Kawakami Yoshiiku, Morio Kei, Kobayashi Tomoki, Yokoyama Satoe, Kimura Yuki, Nagaoki Yuko, Kawaoka Tomokazu, Tsuge Masataka, Hiramatsu Akira, Nelson Hayes C, Aikata Hiroshi, Takahashi Shoichi, Miki Daiki, Ochi Hidenori, Mori Nami, Takaki Shintaro, Tsuji Keiji, Chayama Kazuaki

Abstract excerpt

BACKGROUND: Daclatasvir and asunaprevir combination therapy has shown a high virological response for chronic genotype 1 hepatitis C virus (HCV)-infected patients. However, the safety and efficacy of the therapy for older patients are unknown. METHODS: One hundred seventy patients younger than 75 years and 139 patients aged 75 years or older with genotype 1 HCV infection were treated for 24 weeks with daclatasvir...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbamates
Share to Drug Administration Schedule

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imidazoles

Share to Isoquinolines

Share to Pyrrolidines

Share to Sulfonamides

Share to Sustained Virologic Response

Share to Valine

Source

Identifiers

PMID: 27631593
DOI: 10.1007/s00535-016-1255-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C.PMID 27631593Read ↗

Favorable efficacy of daclatasvir plus asunaprevir in treatment of elderly Japanese patients infected with HCV genotype 1b aged 70 and older.Semantic proximity Read ↗

Direct-acting antivirals are effective for chronic hepatitis C treatment in elderly patients: a real-world study of 17 487 patients.Semantic proximity Read ↗

Efficacy and safety of direct-acting antiviral therapy for hepatitis C virus in elderly patients (≥65 years old): A systematic review and meta-analysis.Semantic proximity Read ↗

Efficacy and safety of glecaprevir and pibrentasvir in Japanese patients with hepatitis C virus infection aged 75 years or older.Semantic proximity Read ↗

Directly acting antivirals are safe and effective in HCV positive patients aged 80 years and older: a multicenter real-life study.Semantic proximity Read ↗

The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yr.Semantic proximity Read ↗

Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older.Semantic proximity Read ↗

Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older.Semantic proximity Read ↗

Efficacy and tolerability of an IFN-free regimen with DCV/ASV for elderly patients infected with HCV genotype 1B.Semantic proximity Read ↗

Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older.Semantic proximity Read ↗

Peginterferon alpha-2a (40 kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients.Semantic proximity Read ↗

Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.